1396PEfficacy and safety of crizotinib in previously treated patients (Pts) with ALK+ advanced non-small cell lung cancer (NSCLC) aged ≥65 years (y). (23rd October 2018) - Moro-Sibilot, D; Ahn, M-J; Halmos, B; Kim, D-W; Riely, G J; Shaw, A T; Yang, P-C; Lanzalone, S; Polli, A; Wilner, K D; De Castro Carpeño, J